keyword
https://read.qxmd.com/read/38226457/lipid-lowering-therapy-implications-of%C3%A2-recent-clinical-trials
#1
REVIEW
James M Backes, Daniel E Hilleman
Recent lipid lowering therapy trials have provided important insights on certain agents while also continuing to expand our understanding of atherosclerotic cardiovascular disease (ASCVD) risk. Findings from current trials include the impact of statin therapy on ASCVD among populations with HIV, the benefit of lowering low-density lipoprotein cholesterol with bempedoic acid among patients considered statin intolerant, the safety and efficacy of inclisiran over a 4-year period, another failed attempt for fibrates to reduce ASCVD risk, which omega-3 fatty to utilize for lowering cardiovascular events, 'n-of-1' trials evaluating statin intolerance, and how low-dose rosuvastatin compared with commonly utilized supplements for lowering lipid parameters...
January 16, 2024: Future Cardiology
https://read.qxmd.com/read/36966799/rosuvastatin-adjunctive-therapy-for-rifampicin-susceptible-pulmonary-tuberculosis-a-phase-2b-randomised-open-label-multicentre-trial
#2
JOURNAL ARTICLE
Gail B Cross, Intan P Sari, Cissy Kityo, Qingshu Lu, Yogesh Pokharkar, Rajesh B Moorakonda, Han-Nguyen Thi, Quyet Do, Victoria B Dalay, Emmanuel Gutierrez, Vincent M Balanag, Randy J Castillo, Henry Mugerwa, Felic Fanusi, Philip Kwan, Ka Lip Chew, Nicholas I Paton
BACKGROUND: Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive statins increase bactericidal activity in preclinical tuberculosis models. We investigated the safety and efficacy of adjunctive rosuvastatin in people with tuberculosis. We tested the hypothesis that adjunctive rosuvastatin accelerates sputum culture conversion within the first 8 weeks of treatment of rifampicin-susceptible tuberculosis. METHODS: This phase 2b, randomised, open-label, multicentre trial conducted in five hospitals or clinics in three countries with high tuberculosis burden (ie, the Philippines, Viet Nam, and Uganda) enrolled adult participants aged 18-75 years with sputum smear or Xpert MTB/RIF positive, rifampicin-susceptible tuberculosis who had received less than 7 days of previous tuberculosis treatment...
March 23, 2023: Lancet Infectious Diseases
https://read.qxmd.com/read/36087110/p-glycoprotein-and-organic-anion-transporter-polypeptide-1b-breast-cancer-resistance-protein-drug-transporter-activity-in-pregnant-women-living-with-hiv
#3
JOURNAL ARTICLE
Fernanda de Lima Moreira, Patrícia Pereira Dos Santos Melli, Maria Paula Marques, Adriana Rocha, Glauco Henrique Balthazar Nardotto, Geraldo Duarte, Vera Lucia Lanchote
This study evaluates the influence of pregnancy and HIV infection in conjunction with the use of raltegravir, lamivudine, and tenofovir disoproxil fumarate (combined antiretroviral therapy [cART]) on intestinal P-glycoprotein (P-gp) and hepatic organic anion transporter polypeptide (OATP) 1B1/1B3 and/or breast cancer resistance protein (BCRP) drug transporter activity using rosuvastatin (OATP1B/BCRP) and fexofenadine (P-gp) probes. Single oral doses of 5-mg rosuvastatin and 60-mg fexofenadine were administered to women living with HIV under cART in the third trimester of gestation (n = 15) and postpartum period (n = 10)...
September 10, 2022: Journal of Clinical Pharmacology
https://read.qxmd.com/read/35642121/a-systematic-review-of-randomized-clinical-trials-on-the-efficacy-and-safety-of-pitavastatin
#4
JOURNAL ARTICLE
Adel Sadeq, Asim Ahmed Elnour, Farah Hamad Farah, Azza Ramadan, Mohamed A Baraka, Judit Don, Abdulla Al Amoodi, Kishore Gnana Sam, Nadia Al Mazrouei, Maisoun Alkaabi
BACKGROUND: A subpopulation of statin users such as subjects with chronic kidney disease (CKD), Human Immune virus (HIV), acute coronary syndrome (ACS), revascularization, metabolic syndrome, and/or diabetes may particularly benefit from pitavastatin pharmacotherapy. AIM: The current systematic review aimed systematically to evaluate the effect of pitavastatin on primary cardiac events in subjects receiving pitavastatin in comparison to the other four statin members...
2023: Curr Rev Clin Exp Pharmacol
https://read.qxmd.com/read/35552635/repurposing-sars-cov-2-main-protease-inhibitors-for-hiv-1-protease-inhibition
#5
JOURNAL ARTICLE
Jacob P Minkkinen, Lisa Gentile
Severe acute respiratory syndrome (SARS-CoV-2) led to the COVID-19 global pandemic, with over 178 million people infected since the start of the pandemic. SARS-CoV-2 is a retrovirus that utilizes a main protease (Mpro ). Mpro is a catalytic cys/his protease. Several treatments were proposed to stop the pandemic including repurposing drugs to inhibit the Mpro . Another retrovirus that uses a protease is human immunodeficiency virus (HIV-1); which has been a global epidemic for 40 years and is a devastating disease that attacks the immune system...
May 2022: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/34820771/anti-inflammatory-effect-of-rosuvastatin-in-patients-with-hiv-infection-an-fdg-pet-pilot-study
#6
JOURNAL ARTICLE
Kevin E Boczar, Elliot Faller, Wanzhen Zeng, Jerry Wang, Gary R Small, Vicente F Corrales-Medina, Robert A deKemp, Natalie C Ward, Rob S B Beanlands, Paul MacPherson, Girish Dwivedi
AIMS: This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin. METHODS AND RESULTS: Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV- control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation...
November 24, 2021: Journal of Nuclear Cardiology
https://read.qxmd.com/read/34398237/effect-of-rosuvastatin-therapy-on-biomarkers-of-inflammation-and-immune-activation-in-people-with-human-immunodeficiency-virus-at-intermediate-cardiovascular-risk
#7
RANDOMIZED CONTROLLED TRIAL
Anna C Hearps, Thomas A Angelovich, Janine M Trevillyan, Michelle E Wong, Alexandra Calmy, Jennifer F Hoy, Anthony Jaworowski
BACKGROUND: Statins may help prevent cardiovascular disease (CVD) in people with human immunodeficiency virus (PWH) with chronic inflammation owing to their pleotropic lipid-lowering and anti-inflammatory properties. METHODS: The impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderate cardiovascular disease risk was assessed. RESULTS: Rosuvastatin did not alter plasma levels of interleukin 6, soluble tumor necrosis factor receptor type 2, CXCL10, soluble CD14, or soluble vascular cellular adhesion molecule 1 (P ≥ ...
August 16, 2021: Journal of Infectious Diseases
https://read.qxmd.com/read/33913752/the-effect-of-rosuvastatin-on-plasma-serum-levels-of-high-sensitivity-c-reactive-protein-interleukin-6-and-d-dimer-in-people-living-with-human-immunodeficiency-virus-a-systematic-review-and-meta-analysis
#8
JOURNAL ARTICLE
Dong-Qing Ye, Akililu Alemu Ashuro, Yin Guang Fan, Yuan-Sheng Fu, Dong-Sheng Di, Napoleon Bellua Sam, Hai-Feng Pan
INTRODUCTION: Rosuvastatin therapy might have effect on inflammatory and coagulation biomarkers. However, the evidence about the effect of Rosuvastatin therapy on the high sensitivity C-reactive protein (hsCRP), Interleukin-6 (IL-6) and D-dimer levels among people living with Human Immunodeficiency Virus (PLHIV) is still unclear. Therefore, this study investigated the relational effect of Rosuvastatin therapy on serum/plasma hsCRP, IL-6 and D-dimer levels in PLHIV. METHODS: The literature search was done from Embase, PUBMED, and Web of Science databases...
April 29, 2021: AIDS Research and Human Retroviruses
https://read.qxmd.com/read/33901017/statin-effect-on-coronary-calcium-distribution-mass-and-volume-scores-and-associations-with-immune-activation-among-hiv-persons-on-antiretroviral-therapy
#9
RANDOMIZED CONTROLLED TRIAL
Jerry Lipinski, Seunghee Margevicius, Mark D Schluchter, David L Wilson, Grace A McComsey, Chris T Longenecker
BACKGROUND: Inflammation has been associated with whole heart coronary artery calcification (CAC) among people with HIV (PWH) on antiretroviral therapy (ART); however, prior studies have not evaluated the distribution of calcium or separated mass versus volume scores, which are differentially associated with clinical events in the general population. Statins may also have a greater effect on CAC mass compared with volume. METHODS: 147 PWH were randomized 1:1 to rosuvastatin 10 mg or placebo and followed for 96 weeks...
2020: Antiviral Therapy
https://read.qxmd.com/read/33620177/reversal-of-viral-latency-and-induction-of-gag-specific-t-cell-responses-in-hiv-1-infected-adults-through-cyclic-treatment-interruption-of-rosuvastatin-a-proof-of-concept-study
#10
JOURNAL ARTICLE
Szu-Min Hsieh, Sung-Ching Pan, Yu-Shan Huang, Shan-Chwen Chang
BACKGROUND: HIV-1 infection remains incurable through combination antiretroviral therapy. Previous studies have shown statins have immunomodulatory effects, and interruption of statins may cause an immune rebound. METHODS: In this proof-of-concept study, we longitudinally assessed the impact of immune rebound by cyclic treatment-interruption (CTI) of rosuvastatin on the reversal of HIV latency. The HIV-1-infected persons with stable viral control were considered to be enrolled for CTI of rosuvastatin with a fixed 12-week interval for 72 weeks (3 treatment-interruption cycles)...
April 1, 2021: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://read.qxmd.com/read/33350447/rosuvastatin-therapy-in-people-with-hiv-at-intermediate-cardiovascular-risk-does-not-decrease-biomarkers-of-inflammation-and-immune-activation
#11
JOURNAL ARTICLE
Anna C Hearps, Thomas A Angelovich, Janine M Trevillyan, Michelle E Wong, Alexandra Calmy, Jennifer F Hoy, Anthony Jaworowski
BACKGROUND: Statins may help prevent cardiovascular disease (CVD) in people with HIV (PWH) with chronic inflammation due to their pleotropic lipid lowering and anti-inflammatory properties. METHODS: The impact of 48 weeks of rosuvastatin therapy on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderate CVD risk was assessed. RESULTS: Rosuvastatin not alter plasma levels of IL-6, soluble (s)TNF-RII, CXCL10, sCD14 or sVCAM-1 (p≥0...
December 22, 2020: Journal of Infectious Diseases
https://read.qxmd.com/read/33252480/impact-of-rosuvastatin-on-atherosclerosis-in-people-with-hiv-at-moderate-cardiovascular-risk-a-randomised-controlled-trial
#12
RANDOMIZED CONTROLLED TRIAL
Janine M Trevillyan, Anthony Dart, Eldho Paul, Matthias Cavassini, Jan Fehr, Cornelia Staehelin, Elizabeth M Dewar, Jennifer F Hoy, Alexandra Calmy
BACKGROUND: People living with HIV-1 (PLHIV) are at increased risk for cardiovascular disease. OBJECTIVE: This study aimed to determine if PLHIV would benefit from starting statins at a lower threshold than currently recommended in the general population. DESIGN: A double-blind multicentre, randomised, placebo-controlled trial was performed. METHODS: Participants (n = 88) with well controlled HIV, at moderate cardiovascular risk (Framingham score of 10-15%), and not recommended for statins were recruited from Australia and Switzerland...
March 15, 2021: AIDS
https://read.qxmd.com/read/33124791/effects-of-exercise-training-and-statin-on-hemodynamic-biochemical-inflammatory-and-immune-profile-of-people-living-with-hiv-a-randomized-double-blind-placebo-controlled-trial
#13
JOURNAL ARTICLE
Hugo R Zanetti, Edmar L Mendes, Alexandre Gonçalves, Leandro T Lopes, Leonardo Roever, Mário L Silva-Vergara, Fernando F Neves, Elmiro S Resende
BACKGROUND: The aim of this study is to evaluate the effect of exercise training (ET) and statins on the hemodynamic, biochemical, inflammatory and immune profile of people living with HIV (PLHIV). METHODS: This was a randomized, double-blind, placebo-controlled clinical trial in which 83 PLHIV were assigned to either placebo (PL), statins (STA), placebo + ET (PLET), or statins + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo...
September 2020: Journal of Sports Medicine and Physical Fitness
https://read.qxmd.com/read/33124006/pharmacokinetic-pharmacodynamic-modelling-to-describe-the-cholesterol-lowering-effect-of-rosuvastatin-in-people-living-with-hiv
#14
JOURNAL ARTICLE
Perrine Courlet, Monia Guidi, Susana Alves Saldanha, Felix Stader, Anna Traytel, Matthias Cavassini, Marcel Stoeckle, Thierry Buclin, Catia Marzolini, Laurent A Decosterd, Chantal Csajka
BACKGROUND: Rosuvastatin is a lipid-lowering agent widely prescribed in people living with HIV, which is actively transported into the liver, making it a potential victim of drug-drug interactions with antiretroviral agents. OBJECTIVES: The aims of this study were to characterise the pharmacokinetic profile of rosuvastatin and to describe the relationship between rosuvastatin concentrations and non-high-density lipoprotein (HDL)-cholesterol levels in people living with HIV...
October 29, 2020: Clinical Pharmacokinetics
https://read.qxmd.com/read/32955957/rosuvastatin-decreases-serum-inflammatory-markers-and-slows-atherosclerosis-progression-rate-in-treated-hiv-infected-patients-with-metabolic-syndrome
#15
JOURNAL ARTICLE
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Giacomo Beci, Fabio Esposito, Isabella Bon, Maria Carla Re, Pierluigi Viale
OBJECTIVES: Metabolic syndrome (MetS) is usually associated in general population with systemic inflammation and higher cardiovascular risk, but data about the effect of statins in patients with HIV infection and MetS are lacking to date. METHODS: Prospective cohort study of treated HIV-infected patients, aged from 40 to 60 years, with or without MetS, who started rosuvastatin (10 mg daily), and were followed-up for 12 months. The primary endpoint was change in serum levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α)...
February 2021: Infectious Diseases
https://read.qxmd.com/read/32351747/psychiatric-disorders-after-switching-to-dolutegravir-a-case-report-of-a-59-year-old-virosuppressed-hiv-1-positive-woman
#16
Daniele Mengato, Raffaella Binazzi, Ivan Unterholzner, Elke M Erne, Alicia Tavella
We report a case of a woman who experienced psychiatric disorders after switching her antiretroviral therapy (c-ART) to dolutegravir (DTG). She is a 59-year-old HIV-1 positive woman with a recent story of cardiovascular disorders treated with beta-blockers, clopidogrel, and rosuvastatin. She underwent a c-ART switch from darunavir/cobicistat and maraviroc to emtricitabine/tenofovir alafenamide fumarate in association with dolutegravir due to drug-drug interactions. One week later, she started to show psychiatric symptoms that required admission to the psychiatric unit...
2020: Case Reports in Infectious Diseases
https://read.qxmd.com/read/32240298/real-life-management-of-drug-drug-interactions-between-antiretrovirals-and-statins
#17
JOURNAL ARTICLE
Perrine Courlet, Françoise Livio, Susana Alves Saldanha, Alexandra Scherrer, Manuel Battegay, Matthias Cavassini, Marcel Stoeckle, Laurent Arthur Decosterd, Catia Marzolini
BACKGROUND: PIs cause drug-drug interactions (DDIs) with most statins due to inhibition of drug-metabolizing enzymes and/or the hepatic uptake transporter OATP1B1, which may alter the pharmacodynamic (PD) effect of statins. OBJECTIVES: To assess the management of DDIs between antiretrovirals (ARVs) and statins in people living with HIV (PLWH) considering statin plasma concentrations, compliance with dosing recommendations and achievement of lipid targets. METHODS: PLWH of the Swiss HIV Cohort Study were eligible if they received a statin concomitantly with ARVs...
July 1, 2020: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/32028327/aging-does-not-impact-drug-drug-interaction-magnitudes-with-antiretrovirals-a-swiss-hiv-cohort-study
#18
JOURNAL ARTICLE
Felix Stader, Laurent Decosterd, Marcel Stoeckle, Matthias Cavassini, Manuel Battegay, Susana Alves Saldanha, Catia Marzolini, Perrine Courlet
The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) due to highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH ≥55 years. DDI magnitudes were comparable to those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar...
February 5, 2020: AIDS
https://read.qxmd.com/read/31834252/effects-of-exercise-training-and-statin-use-in-people-living-with-human-immunodeficiency-virus-with-dyslipidemia
#19
RANDOMIZED CONTROLLED TRIAL
Hugo Ribeiro Zanetti, Alexandre Gonçalves, Leandro Teixeira Paranhos Lopes, Edmar Lacerda Mendes, Leonardo Roever, Mário Leon Silva-Vergara, Fernando Freitas Neves, Elmiro Santos Resende
PURPOSE: To evaluate the effects of the combination of exercise training (ET) and statins in people living with human immunodeficiency virus. METHODS: This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with human immunodeficiency virus were assigned to either placebo (PL), statins (STA), PL + ET (PLET) or STA + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo...
January 2020: Medicine and Science in Sports and Exercise
https://read.qxmd.com/read/31389909/effects-of-exercise-training-and-statin-use-in-people-living-with-hiv-with-dyslipidemia
#20
JOURNAL ARTICLE
Hugo Ribeiro Zanetti, Alexandre Gonçalves, Leandro Teixeira Paranhos Lopes, Edmar Lacerda Mendes, Leonardo Roever, Mário Leon Silva-Vergara, Fernando Freitas Neves, Elmiro Santos Resende
PURPOSE: To evaluate the effects of the combination of ET and statins in people living with HIV. METHODS: This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with HIV were assigned to either placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo. PLET and STAET groups performed ET three times a week...
August 5, 2019: Medicine and Science in Sports and Exercise
keyword
keyword
14750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.